Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance

Sabrina J. Merat, Camille Bru, Dorien van de Berg, Richard Molenkamp, Alexander W. Tarr, Sylvie Koekkoek, Neeltje A. Kootstra, Maria Prins, Jonathan K. Ball, Arjen Q. Bakker, Menno D. de Jong, Hergen Spits, Tim Beaumont, Janke Schinkel

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background & Aims: In order to design an effective vaccine against hepatitis C virus (HCV) infection, it is necessary to understand immune protection. A number of broadly reactive neutralizing antibodies have been isolated from B cells of HCV-infected patients. However, it remains unclear whether B cells producing such antibodies contribute to HCV clearance and long-term immune protection against HCV. Methods: We analysed the B cell repertoire of 13 injecting drug users from the Amsterdam Cohort Study, who were followed up for a median of 17.5 years after primary infection. Individuals were classified into 2 groups based on the outcome of HCV infection: 5 who became chronically infected either after primary infection or after reinfection, and 8 who were HCV RNA negative following spontaneous clearance of ≥1 HCV infection(s). From each individual, 10,000 CD27+IgG+B cells, collected 0.75 year after HCV infection, were cultured to characterize the antibody repertoire. Results: Using a multiplex flow cytometry-based assay to study the antibody binding to E1E2 from genotype 1 to 6, we found that a high frequency of cross-genotype antibodies was associated with spontaneous clearance of 1 or multiple infections (p = 0.03). Epitope specificity of these cross-genotype antibodies was determined by alanine mutant scanning in 4 individuals who were HCV RNA negative following spontaneous clearance of 1 or multiple infections. Interestingly, the cross-genotype antibodies were mainly antigenic region 3 (AR3)-specific and showed cross-neutralizing activity against HCV. In addition to AR3 antibodies, 3 individuals developed antibodies recognizing antigenic region 4, of which 1 monoclonal antibody showed cross-neutralizing capacity. Conclusions: Together, these data suggest that a strong B cell response producing cross-genotype and neutralizing antibodies, especially targeting AR3, contributes to HCV clearance and long-term immune protection against HCV. Lay summary: Although effective treatments against hepatitis C virus (HCV) are available, 500,000 people die from liver disease caused by HCV each year and approximately 1.75 million people are newly infected. This could be prevented by a vaccine. To design a vaccine against HCV, more insight into the role of antibodies in the protection against HCV infection is needed. In a cohort of injecting drug users, we found that antibodies interfering with virus cell entry, and recognizing multiple HCV genotypes, conferred long-term protection against chronic HCV infection.
Original languageEnglish
Pages (from-to)14-24
JournalJournal of Hepatology
Volume71
Issue number1
DOIs
Publication statusPublished - 2019

Cite this

Merat, S. J., Bru, C., van de Berg, D., Molenkamp, R., Tarr, A. W., Koekkoek, S., ... Schinkel, J. (2019). Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance. Journal of Hepatology, 71(1), 14-24. https://doi.org/10.1016/j.jhep.2019.02.013
Merat, Sabrina J. ; Bru, Camille ; van de Berg, Dorien ; Molenkamp, Richard ; Tarr, Alexander W. ; Koekkoek, Sylvie ; Kootstra, Neeltje A. ; Prins, Maria ; Ball, Jonathan K. ; Bakker, Arjen Q. ; de Jong, Menno D. ; Spits, Hergen ; Beaumont, Tim ; Schinkel, Janke. / Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance. In: Journal of Hepatology. 2019 ; Vol. 71, No. 1. pp. 14-24.
@article{a778996733044f6eb0d11d302e9a3df3,
title = "Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance",
abstract = "Background & Aims: In order to design an effective vaccine against hepatitis C virus (HCV) infection, it is necessary to understand immune protection. A number of broadly reactive neutralizing antibodies have been isolated from B cells of HCV-infected patients. However, it remains unclear whether B cells producing such antibodies contribute to HCV clearance and long-term immune protection against HCV. Methods: We analysed the B cell repertoire of 13 injecting drug users from the Amsterdam Cohort Study, who were followed up for a median of 17.5 years after primary infection. Individuals were classified into 2 groups based on the outcome of HCV infection: 5 who became chronically infected either after primary infection or after reinfection, and 8 who were HCV RNA negative following spontaneous clearance of ≥1 HCV infection(s). From each individual, 10,000 CD27+IgG+B cells, collected 0.75 year after HCV infection, were cultured to characterize the antibody repertoire. Results: Using a multiplex flow cytometry-based assay to study the antibody binding to E1E2 from genotype 1 to 6, we found that a high frequency of cross-genotype antibodies was associated with spontaneous clearance of 1 or multiple infections (p = 0.03). Epitope specificity of these cross-genotype antibodies was determined by alanine mutant scanning in 4 individuals who were HCV RNA negative following spontaneous clearance of 1 or multiple infections. Interestingly, the cross-genotype antibodies were mainly antigenic region 3 (AR3)-specific and showed cross-neutralizing activity against HCV. In addition to AR3 antibodies, 3 individuals developed antibodies recognizing antigenic region 4, of which 1 monoclonal antibody showed cross-neutralizing capacity. Conclusions: Together, these data suggest that a strong B cell response producing cross-genotype and neutralizing antibodies, especially targeting AR3, contributes to HCV clearance and long-term immune protection against HCV. Lay summary: Although effective treatments against hepatitis C virus (HCV) are available, 500,000 people die from liver disease caused by HCV each year and approximately 1.75 million people are newly infected. This could be prevented by a vaccine. To design a vaccine against HCV, more insight into the role of antibodies in the protection against HCV infection is needed. In a cohort of injecting drug users, we found that antibodies interfering with virus cell entry, and recognizing multiple HCV genotypes, conferred long-term protection against chronic HCV infection.",
author = "Merat, {Sabrina J.} and Camille Bru and {van de Berg}, Dorien and Richard Molenkamp and Tarr, {Alexander W.} and Sylvie Koekkoek and Kootstra, {Neeltje A.} and Maria Prins and Ball, {Jonathan K.} and Bakker, {Arjen Q.} and {de Jong}, {Menno D.} and Hergen Spits and Tim Beaumont and Janke Schinkel",
year = "2019",
doi = "10.1016/j.jhep.2019.02.013",
language = "English",
volume = "71",
pages = "14--24",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "1",

}

Merat, SJ, Bru, C, van de Berg, D, Molenkamp, R, Tarr, AW, Koekkoek, S, Kootstra, NA, Prins, M, Ball, JK, Bakker, AQ, de Jong, MD, Spits, H, Beaumont, T & Schinkel, J 2019, 'Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance' Journal of Hepatology, vol. 71, no. 1, pp. 14-24. https://doi.org/10.1016/j.jhep.2019.02.013

Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance. / Merat, Sabrina J.; Bru, Camille; van de Berg, Dorien; Molenkamp, Richard; Tarr, Alexander W.; Koekkoek, Sylvie; Kootstra, Neeltje A.; Prins, Maria; Ball, Jonathan K.; Bakker, Arjen Q.; de Jong, Menno D.; Spits, Hergen; Beaumont, Tim; Schinkel, Janke.

In: Journal of Hepatology, Vol. 71, No. 1, 2019, p. 14-24.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance

AU - Merat, Sabrina J.

AU - Bru, Camille

AU - van de Berg, Dorien

AU - Molenkamp, Richard

AU - Tarr, Alexander W.

AU - Koekkoek, Sylvie

AU - Kootstra, Neeltje A.

AU - Prins, Maria

AU - Ball, Jonathan K.

AU - Bakker, Arjen Q.

AU - de Jong, Menno D.

AU - Spits, Hergen

AU - Beaumont, Tim

AU - Schinkel, Janke

PY - 2019

Y1 - 2019

N2 - Background & Aims: In order to design an effective vaccine against hepatitis C virus (HCV) infection, it is necessary to understand immune protection. A number of broadly reactive neutralizing antibodies have been isolated from B cells of HCV-infected patients. However, it remains unclear whether B cells producing such antibodies contribute to HCV clearance and long-term immune protection against HCV. Methods: We analysed the B cell repertoire of 13 injecting drug users from the Amsterdam Cohort Study, who were followed up for a median of 17.5 years after primary infection. Individuals were classified into 2 groups based on the outcome of HCV infection: 5 who became chronically infected either after primary infection or after reinfection, and 8 who were HCV RNA negative following spontaneous clearance of ≥1 HCV infection(s). From each individual, 10,000 CD27+IgG+B cells, collected 0.75 year after HCV infection, were cultured to characterize the antibody repertoire. Results: Using a multiplex flow cytometry-based assay to study the antibody binding to E1E2 from genotype 1 to 6, we found that a high frequency of cross-genotype antibodies was associated with spontaneous clearance of 1 or multiple infections (p = 0.03). Epitope specificity of these cross-genotype antibodies was determined by alanine mutant scanning in 4 individuals who were HCV RNA negative following spontaneous clearance of 1 or multiple infections. Interestingly, the cross-genotype antibodies were mainly antigenic region 3 (AR3)-specific and showed cross-neutralizing activity against HCV. In addition to AR3 antibodies, 3 individuals developed antibodies recognizing antigenic region 4, of which 1 monoclonal antibody showed cross-neutralizing capacity. Conclusions: Together, these data suggest that a strong B cell response producing cross-genotype and neutralizing antibodies, especially targeting AR3, contributes to HCV clearance and long-term immune protection against HCV. Lay summary: Although effective treatments against hepatitis C virus (HCV) are available, 500,000 people die from liver disease caused by HCV each year and approximately 1.75 million people are newly infected. This could be prevented by a vaccine. To design a vaccine against HCV, more insight into the role of antibodies in the protection against HCV infection is needed. In a cohort of injecting drug users, we found that antibodies interfering with virus cell entry, and recognizing multiple HCV genotypes, conferred long-term protection against chronic HCV infection.

AB - Background & Aims: In order to design an effective vaccine against hepatitis C virus (HCV) infection, it is necessary to understand immune protection. A number of broadly reactive neutralizing antibodies have been isolated from B cells of HCV-infected patients. However, it remains unclear whether B cells producing such antibodies contribute to HCV clearance and long-term immune protection against HCV. Methods: We analysed the B cell repertoire of 13 injecting drug users from the Amsterdam Cohort Study, who were followed up for a median of 17.5 years after primary infection. Individuals were classified into 2 groups based on the outcome of HCV infection: 5 who became chronically infected either after primary infection or after reinfection, and 8 who were HCV RNA negative following spontaneous clearance of ≥1 HCV infection(s). From each individual, 10,000 CD27+IgG+B cells, collected 0.75 year after HCV infection, were cultured to characterize the antibody repertoire. Results: Using a multiplex flow cytometry-based assay to study the antibody binding to E1E2 from genotype 1 to 6, we found that a high frequency of cross-genotype antibodies was associated with spontaneous clearance of 1 or multiple infections (p = 0.03). Epitope specificity of these cross-genotype antibodies was determined by alanine mutant scanning in 4 individuals who were HCV RNA negative following spontaneous clearance of 1 or multiple infections. Interestingly, the cross-genotype antibodies were mainly antigenic region 3 (AR3)-specific and showed cross-neutralizing activity against HCV. In addition to AR3 antibodies, 3 individuals developed antibodies recognizing antigenic region 4, of which 1 monoclonal antibody showed cross-neutralizing capacity. Conclusions: Together, these data suggest that a strong B cell response producing cross-genotype and neutralizing antibodies, especially targeting AR3, contributes to HCV clearance and long-term immune protection against HCV. Lay summary: Although effective treatments against hepatitis C virus (HCV) are available, 500,000 people die from liver disease caused by HCV each year and approximately 1.75 million people are newly infected. This could be prevented by a vaccine. To design a vaccine against HCV, more insight into the role of antibodies in the protection against HCV infection is needed. In a cohort of injecting drug users, we found that antibodies interfering with virus cell entry, and recognizing multiple HCV genotypes, conferred long-term protection against chronic HCV infection.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85064159325&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30797052

U2 - 10.1016/j.jhep.2019.02.013

DO - 10.1016/j.jhep.2019.02.013

M3 - Article

VL - 71

SP - 14

EP - 24

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 1

ER -